Susan Jane Ripper, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Pacific Internal Medicine Associates · 5 clinicians in this group
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ripper’s office at (415) 923-3878 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A113278 · Current
Licensed to practise in California · since 2010 · expires 2028-06-30 · University of Colorado School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$363,943
Medicare paid this office $363,943 for 583 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 156 | $26,445 | $116 |
| Biopsy of large bowel using a flexible endoscope | 140 | $22,211 | $159 |
| Short return visit (20+ min) | 116 | $16,145 | $78 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 131 | $11,773 | $90 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 46 | $9,422 | $205 |
See all 13 services
| Return visit (30+ min) | 156 | $26,445 | $116 |
| Biopsy of large bowel using a flexible endoscope | 140 | $22,211 | $159 |
| Short return visit (20+ min) | 116 | $16,145 | $78 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 131 | $11,773 | $90 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 46 | $9,422 | $205 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $9,220 | $126 |
| New patient visit (45+ min) | 62 | $9,035 | $146 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $7,892 | $213 |
| Telephone medical discussion with physician, 21-30 minutes | 46 | $7,289 | $114 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 34 | $6,977 | $205 |
| Telephone medical discussion with physician, 11-20 minutes | 47 | $5,634 | $85 |
| Diagnostic exam of large bowel using a flexible endoscope | 37 | $5,529 | $149 |
| Infusion, normal saline solution, 250 cc | 14 | $66 | None |
Procedures Medicare counted
| Colonoscopy | 296 | More than 97% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 113 | More than 79% of doctors who do this |
Who their Medicare patients are
583 Original Medicare patients in 2024. Average age 75 · Women 76% · Also on Medicaid 4% · Health risk score 0.90. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 54% · Cancer 20% · Coronary heart disease 19% · Depression 17% · Diabetes 13% · Chronic kidney disease 10% · Atrial fibrillation 10% · COPD 9% · Heart failure 7% · Stroke 5% · Dementia 3%.
The office billed $1,184,660, Medicare allowed $464,515 and paid $363,943; for 13,536 services of 28 kinds; $220,790 of it was for drugs given in the office and $143,154 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 583 | 13,536 | 75 | 0.90 | $1,184,660 | $363,943 |
| 2023 | 514 | 12,714 | 75 | 0.82 | $1,071,860 | $334,698 |
| 2022 | 590 | 17,199 | 74 | 0.79 | $1,304,660 | $410,503 |
| 2021 | 534 | 13,137 | 74 | 0.83 | $1,225,825 | $360,965 |
| 2020 | 459 | 9,500 | 73 | 0.94 | $1,017,050 | $295,692 |
| 2019 | 421 | 8,626 | 74 | 1.14 | $966,065 | $303,575 |
| 2018 | 536 | 6,108 | 74 | 1.05 | $886,795 | $268,243 |
| 2017 | 409 | 6,570 | 73 | 1.01 | $699,295 | $212,653 |
| 2016 | 328 | 636 | 73 | 1.09 | $304,140 | $68,396 |
| 2015 | 114 | 166 | 72 | 1.70 | $87,770 | $21,853 |
| 2014 | 34 | 48 | 67 | 3.12 | $26,352 | $6,939 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Biopsy of large bowel using a flexible endoscope | 133 | $22,422 | $169 |
| Return visit (30+ min) | 107 | $19,201 | $118 |
| Short return visit (20+ min) | 115 | $17,610 | $83 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 48 | $9,736 | $203 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $9,726 | $94 |
| New patient visit (45+ min) | 49 | $7,478 | $153 |
| Telephone medical discussion with physician, 21-30 minutes | 44 | $6,229 | $120 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 27 | $5,637 | $209 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 25 | $5,075 | $203 |
| Telephone medical discussion with physician, 11-20 minutes | 39 | $4,409 | $80 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $3,245 | $162 |
| Infusion, normal saline solution, 250 cc | 12 | $93 | None |
2022: 14 services
| Short return visit (20+ min) | 177 | $22,534 | $75 |
| Biopsy of large bowel using a flexible endoscope | 140 | $20,954 | $149 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 82 | $16,842 | $205 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 117 | $10,905 | $93 |
| Return visit (30+ min) | 86 | $10,762 | $111 |
| New patient visit (45+ min) | 50 | $6,923 | $138 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 34 | $6,453 | $190 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 29 | $5,973 | $206 |
| Telephone medical discussion with physician, 11-20 minutes | 37 | $4,352 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $3,229 | $67 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $2,882 | $152 |
| New patient visit (30+ min) | 19 | $1,565 | $82 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,341 | $96 |
| Infusion, normal saline solution, 250 cc | 20 | $65 | None |
2021: 12 services
| Short return visit (20+ min) | 207 | $31,460 | $78 |
| Biopsy of large bowel using a flexible endoscope | 160 | $23,775 | $149 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 138 | $12,786 | $92 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 60 | $12,581 | $210 |
| Return visit (30+ min) | 74 | $8,709 | $110 |
| New patient visit (45+ min) | 53 | $7,409 | $140 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 27 | $5,754 | $213 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 24 | $5,036 | $210 |
| Diagnostic exam of large bowel using a flexible endoscope | 25 | $3,998 | $160 |
| New patient visit (30+ min) | 27 | $2,560 | $95 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $2,002 | $83 |
| Infusion, normal saline solution, 250 cc | 12 | $49 | None |
2020: 12 services
| Short return visit (20+ min) | 188 | $25,406 | $68 |
| Biopsy of large bowel using a flexible endoscope | 153 | $22,741 | $149 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 118 | $10,097 | $83 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 40 | $8,535 | $213 |
| Return visit (30+ min) | 67 | $7,858 | $94 |
| New patient visit (45+ min) | 56 | $7,630 | $136 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $5,368 | $192 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,212 | $214 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $2,003 | $69 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $1,859 | $143 |
| New patient visit (30+ min) | 13 | $936 | $72 |
| Infusion, normal saline solution, 250 cc | 12 | $34 | None |
2019: 10 services
| Biopsy of large bowel using a flexible endoscope | 125 | $19,035 | $152 |
| Short return visit (20+ min) | 154 | $11,290 | $58 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 51 | $10,861 | $213 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 104 | $9,592 | $91 |
| New patient visit (45+ min) | 48 | $6,478 | $135 |
| Return visit (30+ min) | 60 | $5,986 | $88 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 26 | $5,637 | $217 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,771 | $213 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,955 | $163 |
| Infusion, normal saline solution, 250 cc | 12 | $33 | None |
2018: 12 services
| Biopsy of large bowel using a flexible endoscope | 143 | $22,044 | $152 |
| Short return visit (20+ min) | 199 | $18,653 | $61 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 130 | $12,832 | $98 |
| New patient visit (45+ min) | 75 | $10,268 | $137 |
| Return visit (30+ min) | 107 | $9,900 | $88 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 33 | $6,944 | $210 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 27 | $6,178 | $221 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 25 | $5,264 | $211 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $2,190 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,026 | $92 |
| New patient visit (30+ min) | 20 | $1,704 | $85 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 26 | $124 | $4 |
2017: 10 services
| Short return visit (20+ min) | 175 | $13,601 | $60 |
| Biopsy of large bowel using a flexible endoscope | 79 | $11,400 | $144 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | $8,676 | $212 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 88 | $8,664 | $97 |
| New patient visit (45+ min) | 44 | $5,788 | $132 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 27 | $5,725 | $212 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 23 | $4,884 | $212 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $3,567 | $170 |
| Return visit (30+ min) | 40 | $3,567 | $89 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 11 | $92 | $8 |
2016: 14 services
| Short return visit (20+ min) | 132 | $12,423 | $64 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 74 | $7,642 | $101 |
| New patient visit (45+ min) | 54 | $7,601 | $141 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 32 | $7,029 | $220 |
| Biopsy of large bowel using a flexible endoscope | 40 | $6,829 | $167 |
| Return visit (30+ min) | 66 | $6,308 | $91 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 19 | $4,170 | $219 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $4,061 | $214 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,721 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,133 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $1,863 | $89 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,845 | $168 |
| New patient visit (30+ min) | 18 | $1,738 | $97 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 15 | $131 | $9 |
2015: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,223 | $174 |
| Return visit (30+ min) | 24 | $2,968 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,981 | $117 |
| Short return visit (20+ min) | 21 | $1,534 | $70 |
2014: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,059 | $181 |
Drugs they prescribed that Part D paid
$1,060,682
Pharmacies billed $1,060,682 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,540 generic and fewer than 11 brand-name prescriptions · $1,060,682 in drug cost · 68 antibiotic prescriptions to 43 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 54 | $181,189 | $3,355 |
| Rinvoq | 25 | $167,668 | $6,707 |
| Linzess | 72 | $74,282 | $1,032 |
| Zenpep | 16 | $65,236 | $4,077 |
| Viberzi | 23 | $42,617 | $1,853 |
See all 29 drugs
| Creon | 54 | $181,189 | $3,355 |
| Rinvoq | 25 | $167,668 | $6,707 |
| Linzess | 72 | $74,282 | $1,032 |
| Zenpep | 16 | $65,236 | $4,077 |
| Viberzi | 23 | $42,617 | $1,853 |
| Xifaxan | 17 | $39,079 | $2,299 |
| Mesalamine | 77 | $30,702 | $399 |
| Dexlansoprazole Dr | 94 | $29,703 | $316 |
| Sod Sulf-Potass Sulf-Mag Sulf | 339 | $21,571 | $64 |
| Mesalamine Er | 33 | $19,430 | $589 |
| Motegrity | 13 | $9,180 | $706 |
| Lubiprostone | 21 | $7,539 | $359 |
| Esomeprazole Magnesium | 40 | $6,465 | $162 |
| Pantoprazole | 289 | $6,097 | $21 |
| Famotidine | 237 | $4,553 | $19 |
| Budesonide Dr | 26 | $3,065 | $118 |
| Sucralfate | 39 | $2,864 | $73 |
| Sutab | 16 | $2,618 | $164 |
| Omeprazole | 222 | $2,434 | $11 |
| Dicyclomine | 85 | $2,070 | $24 |
| Diphenoxylate-Atropine | 41 | $1,109 | $27 |
| Lansoprazole | 15 | $456 | $30 |
| Ondansetron | 22 | $363 | $17 |
| Nortriptyline | 14 | $272 | $19 |
| Ciprofloxacin | 13 | $149 | $11 |
| Amitriptyline | 13 | $115 | $9 |
| Lorazepam | 16 | $109 | $7 |
| Metronidazole | 12 | $86 | $7 |
| Amoxicillin-Clavulanate Potass | 14 | $69 | $5 |
Year by year
| 2024 | 2,096 | 717 | None | None | $1,060,682 |
| 2023 | 2,087 | 674 | None | 26% | $932,189 |
| 2022 | 2,170 | 684 | None | None | $984,476 |
| 2021 | 2,124 | 633 | 1% (11) | None | $955,677 |
| 2020 | 1,857 | 532 | None | 38% | $824,919 |
| 2019 | 1,935 | 496 | None | None | $595,472 |
| 2018 | 1,892 | 554 | None | None | $456,879 |
| 2017 | 988 | 328 | None | None | $388,949 |
| 2016 | 526 | 210 | 3% (14) | None | $170,977 |
| 2015 | 62 | 35 | None | 35% | $22,347 |
| 2014 | 29 | None | 0% (0) | None | $22,163 |
| 2013 | 29 | None | 0% (0) | None | $14,456 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Creon | 32 | $141,442 | $4,420 |
| Linzess | 80 | $74,145 | $927 |
| Mesalamine | 66 | $46,795 | $709 |
| Dexlansoprazole Dr | 95 | $41,774 | $440 |
| Sod Sulf-Potass Sulf-Mag Sulf | 288 | $22,223 | $77 |
| Mesalamine Er | 31 | $18,398 | $593 |
| Viberzi | 11 | $18,109 | $1,646 |
| Dexilant | 16 | $12,103 | $756 |
| Trulance | 16 | $11,275 | $705 |
| Lubiprostone | 24 | $10,032 | $418 |
| Budesonide Ec | 21 | $9,996 | $476 |
| Pantoprazole | 322 | $8,057 | $25 |
| Sucralfate | 45 | $8,043 | $179 |
| Famotidine | 230 | $5,634 | $24 |
| Omeprazole | 235 | $3,873 | $16 |
| Sutab | 22 | $3,734 | $170 |
| Budesonide Dr | 30 | $3,636 | $121 |
| Balsalazide Disodium | 17 | $2,829 | $166 |
| Suprep | 22 | $2,713 | $123 |
| Cholestyramine | 11 | $2,094 | $190 |
| Dicyclomine | 99 | $1,959 | $20 |
| Esomeprazole Magnesium | 34 | $1,793 | $53 |
| Lansoprazole | 14 | $1,320 | $94 |
| Ondansetron Odt | 16 | $839 | $52 |
| Diphenoxylate-Atropine | 23 | $838 | $36 |
| Hyoscyamine Sulfate | 17 | $619 | $36 |
| Ciprofloxacin | 17 | $204 | $12 |
| Metronidazole | 19 | $159 | $8 |
| Nortriptyline | 21 | $123 | $6 |
2022: 31 drugs
| Creon | 31 | $148,507 | $4,791 |
| Humira(Cf) | 12 | $82,594 | $6,883 |
| Linzess | 97 | $71,822 | $740 |
| Mesalamine | 86 | $54,897 | $638 |
| Dexilant | 80 | $47,126 | $589 |
| Suprep | 268 | $30,906 | $115 |
| Mesalamine Er | 49 | $30,553 | $624 |
| Zenpep | 12 | $28,842 | $2,403 |
| Xifaxan | 12 | $26,511 | $2,209 |
| Viberzi | 14 | $21,752 | $1,554 |
| Dexlansoprazole Dr | 40 | $17,295 | $432 |
| Lubiprostone | 30 | $14,774 | $492 |
| Pantoprazole | 386 | $8,824 | $23 |
| Amitiza | 13 | $7,492 | $576 |
| Budesonide Ec | 18 | $7,145 | $397 |
| Sod Sulf-Potass Sulf-Mag Sulf | 80 | $6,440 | $81 |
| Sucralfate | 57 | $6,331 | $111 |
| Cholestyramine | 18 | $5,642 | $313 |
| Famotidine | 198 | $5,395 | $27 |
| Omeprazole | 217 | $3,305 | $15 |
| Budesonide Dr | 32 | $2,709 | $85 |
| Colestipol | 11 | $2,482 | $226 |
| Esomeprazole Magnesium | 19 | $2,438 | $128 |
| Balsalazide Disodium | 14 | $2,137 | $153 |
| Diphenoxylate-Atropine | 29 | $1,100 | $38 |
| Dicyclomine | 67 | $1,088 | $16 |
| Ondansetron Odt | 14 | $299 | $21 |
| Metoclopramide | 14 | $277 | $20 |
| Nortriptyline | 11 | $213 | $19 |
| Ciprofloxacin | 18 | $167 | $9 |
| Metronidazole | 16 | $66 | $4 |
2021: 29 drugs
| Humira | 14 | $171,294 | $12,235 |
| Creon | 39 | $140,570 | $3,604 |
| Mesalamine | 103 | $69,285 | $673 |
| Linzess | 86 | $63,697 | $741 |
| Dexilant | 101 | $63,268 | $626 |
| Xeljanz | 12 | $57,261 | $4,772 |
| Suprep | 368 | $41,264 | $112 |
| Mesalamine Er | 35 | $18,019 | $515 |
| Motegrity | 22 | $14,126 | $642 |
| Amitiza | 28 | $12,713 | $454 |
| Lubiprostone | 23 | $9,715 | $422 |
| Budesonide Ec | 18 | $9,510 | $528 |
| Pantoprazole | 335 | $6,793 | $20 |
| Cholestyramine | 18 | $5,729 | $318 |
| Sucralfate | 53 | $4,832 | $91 |
| Famotidine | 163 | $4,513 | $28 |
| Budesonide Dr | 21 | $4,171 | $199 |
| Omeprazole | 241 | $3,907 | $16 |
| Hydrocortisone | 17 | $2,713 | $160 |
| Balsalazide Disodium | 17 | $2,707 | $159 |
| Diphenoxylate-Atropine | 30 | $1,693 | $56 |
| Ondansetron Odt | 27 | $1,513 | $56 |
| Esomeprazole Magnesium | 22 | $879 | $40 |
| Dicyclomine | 70 | $877 | $13 |
| Nortriptyline | 17 | $382 | $22 |
| Metoclopramide | 15 | $186 | $12 |
| Amoxicillin-Clavulanate Potass | 11 | $145 | $13 |
| Buspirone | 12 | $115 | $10 |
| Metronidazole | 14 | $109 | $8 |
2020: 24 drugs
| Creon | 49 | $133,539 | $2,725 |
| Mesalamine | 105 | $74,426 | $709 |
| Dexilant | 93 | $56,000 | $602 |
| Linzess | 56 | $35,987 | $643 |
| Amitiza | 59 | $32,637 | $553 |
| Suprep | 269 | $28,305 | $105 |
| Xifaxan | 13 | $23,743 | $1,826 |
| Mesalamine Er | 39 | $21,073 | $540 |
| Budesonide Ec | 28 | $19,207 | $686 |
| Pantoprazole | 337 | $8,144 | $24 |
| Sucralfate | 46 | $7,160 | $156 |
| Cholestyramine | 24 | $6,171 | $257 |
| Balsalazide Disodium | 19 | $3,906 | $206 |
| Famotidine | 101 | $3,336 | $33 |
| Omeprazole | 196 | $3,177 | $16 |
| Diphenoxylate-Atropine | 18 | $1,506 | $84 |
| Ondansetron Odt | 26 | $1,044 | $40 |
| Esomeprazole Magnesium | 28 | $1,015 | $36 |
| Desipramine | 11 | $798 | $73 |
| Dicyclomine | 43 | $653 | $15 |
| Nortriptyline | 13 | $256 | $20 |
| Ciprofloxacin | 25 | $199 | $8 |
| Metronidazole | 27 | $183 | $7 |
| Metoclopramide | 12 | $173 | $14 |
2019: 25 drugs
| Creon | 41 | $72,390 | $1,766 |
| Mesalamine | 82 | $68,339 | $833 |
| Dexilant | 120 | $53,765 | $448 |
| Apriso | 68 | $48,219 | $709 |
| Amitiza | 67 | $36,209 | $540 |
| Linzess | 46 | $29,907 | $650 |
| Vemlidy | 12 | $26,559 | $2,213 |
| Suprep | 208 | $20,758 | $100 |
| Budesonide Ec | 27 | $16,075 | $595 |
| Pantoprazole | 306 | $6,621 | $22 |
| Carafate | 21 | $5,967 | $284 |
| Cholestyramine | 42 | $5,618 | $134 |
| Ursodiol | 11 | $5,469 | $497 |
| Omeprazole | 224 | $3,486 | $16 |
| Ranitidine | 168 | $3,235 | $19 |
| Esomeprazole Magnesium | 32 | $2,844 | $89 |
| Sucralfate | 47 | $1,236 | $26 |
| Diphenoxylate-Atropine | 18 | $941 | $52 |
| Famotidine | 34 | $842 | $25 |
| Loperamide | 11 | $709 | $64 |
| Dicyclomine | 52 | $706 | $14 |
| Ondansetron Odt | 25 | $540 | $22 |
| Nortriptyline | 33 | $393 | $12 |
| Ciprofloxacin | 17 | $228 | $13 |
| Metronidazole | 18 | $167 | $9 |
2018: 29 drugs
| Mesalamine | 67 | $61,347 | $916 |
| Dexilant | 131 | $55,431 | $423 |
| Apriso | 79 | $52,304 | $662 |
| Creon | 13 | $29,262 | $2,251 |
| Suprep | 278 | $26,264 | $94 |
| Amitiza | 54 | $25,825 | $478 |
| Canasa | 22 | $24,933 | $1,133 |
| Lialda | 15 | $23,621 | $1,575 |
| Linzess | 31 | $22,845 | $737 |
| Xifaxan | 12 | $18,120 | $1,510 |
| Budesonide Ec | 16 | $15,155 | $947 |
| Carafate | 44 | $13,150 | $299 |
| Ursodiol | 11 | $5,810 | $528 |
| Cholestyramine | 38 | $5,210 | $137 |
| Pantoprazole | 229 | $4,023 | $18 |
| Omeprazole | 208 | $3,377 | $16 |
| Esomeprazole Magnesium | 36 | $3,035 | $84 |
| Ranitidine | 140 | $2,169 | $15 |
| Sucralfate | 41 | $1,460 | $36 |
| Polyethylene Glycol 3350 | 23 | $1,203 | $52 |
| Diphenoxylate-Atropine | 28 | $1,126 | $40 |
| Loperamide | 11 | $558 | $51 |
| Dicyclomine | 59 | $443 | $8 |
| Ondansetron Odt | 15 | $285 | $19 |
| Nortriptyline | 35 | $252 | $7 |
| Metronidazole | 30 | $210 | $7 |
| Metoclopramide | 19 | $192 | $10 |
| Famotidine | 23 | $192 | $8 |
| Ciprofloxacin | 27 | $172 | $6 |
2017: 25 drugs
| Dexilant | 72 | $29,176 | $405 |
| Lialda | 30 | $25,829 | $861 |
| Xifaxan | 13 | $18,359 | $1,412 |
| Amitiza | 31 | $15,904 | $513 |
| Creon | 11 | $15,531 | $1,412 |
| Mesalamine | 17 | $12,899 | $759 |
| Apriso | 29 | $11,142 | $384 |
| Budesonide Ec | 18 | $11,025 | $613 |
| Suprep | 117 | $10,307 | $88 |
| Linzess | 16 | $7,316 | $457 |
| Carafate | 33 | $7,014 | $213 |
| Esomeprazole Magnesium | 15 | $2,499 | $167 |
| Pantoprazole | 134 | $2,255 | $17 |
| Cholestyramine | 18 | $1,747 | $97 |
| Omeprazole | 95 | $1,300 | $14 |
| Sucralfate | 14 | $869 | $62 |
| Diphenoxylate-Atropine | 18 | $754 | $42 |
| Ranitidine | 59 | $510 | $9 |
| Polyethylene Glycol 3350 | 11 | $275 | $25 |
| Ondansetron Odt | 12 | $239 | $20 |
| Ciprofloxacin | 17 | $200 | $12 |
| Dicyclomine | 33 | $160 | $5 |
| Nortriptyline | 23 | $138 | $6 |
| Metronidazole | 18 | $119 | $7 |
| Famotidine | 15 | $99 | $7 |
2016: 13 drugs
| Budesonide Ec | 17 | $9,495 | $559 |
| Suprep | 102 | $8,485 | $83 |
| Dexilant | 18 | $6,267 | $348 |
| Amitiza | 13 | $4,835 | $372 |
| Carafate | 17 | $2,855 | $168 |
| Pantoprazole | 66 | $1,391 | $21 |
| Diphenoxylate-Atropine | 26 | $841 | $32 |
| Omeprazole | 55 | $817 | $15 |
| Metronidazole | 25 | $278 | $11 |
| Ciprofloxacin | 20 | $194 | $10 |
| Nortriptyline | 12 | $114 | $10 |
| Dicyclomine | 14 | $67 | $5 |
| Tramadol | 11 | $28 | $3 |
Money from drug and device companies
$4,518 in 2025
| 2025 | 15 | 167 | None | $4,518 |
| 2024 | 19 | 123 | None | $2,941 |
| 2023 | 16 | 123 | None | $2,722 |
| 2022 | 8 | 113 | None | $2,126 |
| 2021 | 6 | 85 | None | $1,548 |
| 2020 | 9 | 46 | None | $933 |
| 2019 | 13 | 86 | None | $1,858 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $1,610 | 62 payments
|
| Janssen Biotech | Tremfya | $686 | 18 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $480 | 23 payments
|
| Gilead Sciences | Livdelzi | $309 | 8 payments
|
| Celltrion USA | Vegzelma | $275 | 11 payments
|
| Pfizer | Xeljanz | $241 | 11 payments
|
See all 167 published payments
| Novo Nordisk | Meals · 2025-12-19 | Wegovy | $29 |
| Abbvie | Meals · 2025-12-19 | Skyrizi | $7 |
| Janssen Biotech | Meals · 2025-12-17 | Tremfya | $28 |
| Abbvie | Meals · 2025-12-17 | Creon | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-16 | Entyvio | $37 |
| Abbvie | Meals · 2025-12-12 | Rinvoq | $25 |
| Abbvie | Meals · 2025-12-12 | Rinvoq | $28 |
| Abbvie | Meals · 2025-12-10 | Creon | $24 |
| Abbvie | Meals · 2025-12-10 | Linzess | $32 |
| Pfizer | Meals · 2025-12-09 | Velsipity | $20 |
| Celltrion USA | Meals · 2025-12-05 | Vegzelma | $24 |
| Abbvie | Meals · 2025-12-03 | Rinvoq | $31 |
| Phathom Pharmaceuticals | Meals · 2025-12-02 | Voquezna | $12 |
| Phathom Pharmaceuticals | Meals · 2025-12-02 | Voquezna | $13 |
| Abbvie | Meals · 2025-11-20 | Linzess | $28 |
| Gilead Sciences | Meals · 2025-11-18 | None | $29 |
| Pfizer | Meals · 2025-11-14 | Velsipity | $26 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-13 | Eohilia | $0 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-13 | Eohilia | $33 |
| Abbvie | Meals · 2025-11-11 | Rinvoq | $21 |
| Ardelyx | Meals · 2025-11-07 | Ibsrela | $25 |
| Novo Nordisk | Meals · 2025-11-05 | Wegovy | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-30 | Entyvio | $29 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $30 |
| Ardelyx | Meals · 2025-10-28 | Ibsrela | $16 |
| Pfizer | Meals · 2025-10-24 | Velsipity | $25 |
| Abbvie | Meals · 2025-10-23 | Skyrizi | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-21 | Entyvio | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-21 | Entyvio | $32 |
| Abbvie | Meals · 2025-10-17 | Rinvoq | $26 |
| Abbvie | Meals · 2025-10-16 | Linzess | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-16 | Entyvio | $10 |
| Braintree Laboratories | Meals · 2025-10-14 | Suflave | $28 |
| Abbvie | Meals · 2025-10-10 | Rinvoq | $25 |
| Abbvie | Meals · 2025-10-09 | Creon | $30 |
| Abbvie | Meals · 2025-10-07 | Rinvoq | $21 |
| Aimmune Therapeutics | Meals · 2025-10-07 | Zenpep | $18 |
| Pfizer | Meals · 2025-10-03 | Velsipity | $20 |
| Janssen Biotech | Meals · 2025-10-02 | Tremfya | $27 |
| Abbvie | Meals · 2025-10-02 | Linzess | $25 |
| Abbvie | Meals · 2025-10-01 | Skyrizi | $23 |
| Celltrion USA | Meals · 2025-09-25 | Vegzelma | $25 |
| Phathom Pharmaceuticals | Meals · 2025-09-24 | Voquezna | $32 |
| Abbvie | Meals · 2025-09-19 | Rinvoq | $19 |
| Abbvie | Meals · 2025-09-18 | Creon | $23 |
| Gilead Sciences | Meals · 2025-09-18 | None | $26 |
| Aimmune Therapeutics | Meals · 2025-09-18 | Zenpep | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-16 | Entyvio | $23 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-16 | Xifaxan | $24 |
| Abbvie | Meals · 2025-09-12 | Skyrizi | $23 |
| Abbvie | Meals · 2025-09-12 | Rinvoq | $24 |
| Abbvie | Meals · 2025-09-10 | Skyrizi | $24 |
| Abbvie | Meals · 2025-09-09 | Rinvoq | $24 |
| Abbvie | Meals · 2025-09-05 | Skyrizi | $28 |
| Abbvie | Meals · 2025-09-04 | Creon | $21 |
| Pfizer | Meals · 2025-09-03 | Xeljanz | $20 |
| Celltrion USA | Meals · 2025-08-29 | Vegzelma | $25 |
| Abbvie | Meals · 2025-08-28 | Creon | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-22 | Entyvio | $23 |
| Abbvie | Meals · 2025-08-21 | Rinvoq | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-21 | Entyvio | $35 |
| Abbvie | Meals · 2025-08-20 | Creon | $26 |
| Abbvie | Meals · 2025-08-15 | Rinvoq | $22 |
| Aimmune Therapeutics | Meals · 2025-08-14 | Zenpep | $29 |
| Abbvie | Meals · 2025-08-08 | Rinvoq | $22 |
| Janssen Biotech | Meals · 2025-08-07 | Tremfya | $28 |
| Abbvie | Meals · 2025-08-07 | Skyrizi | $30 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $28 |
| Celltrion USA | Meals · 2025-07-28 | Vegzelma | $23 |
| Ardelyx | Meals · 2025-07-18 | Ibsrela | $23 |
| Aimmune Therapeutics | Meals · 2025-07-17 | Zenpep | $27 |
| Celltrion USA | Meals · 2025-07-17 | Vegzelma | $20 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $32 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-14 | Entyvio | $23 |
| Abbvie | Meals · 2025-07-11 | Skyrizi | $25 |
| Abbvie | Meals · 2025-07-11 | Rinvoq | $28 |
| Abbvie | Meals · 2025-07-09 | Creon | $23 |
| Pfizer | Meals · 2025-07-09 | Xeljanz | $26 |
| Abbvie | Meals · 2025-07-02 | Rinvoq | $23 |
| Ardelyx | Meals · 2025-07-01 | Ibsrela | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-06-27 | Dupixent | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-06-27 | Rezdiffra | $31 |
| Janssen Biotech | Education · 2025-06-24 | Tremfya | $85 |
| Lilly USA | Meals · 2025-06-24 | Omvoh | $32 |
| Gilead Sciences | Meals · 2025-06-24 | None | $3 |
| Aimmune Therapeutics | Meals · 2025-06-24 | Zenpep | $31 |
| Janssen Biotech | Meals · 2025-06-19 | Tremfya | $27 |
| Abbvie | Meals · 2025-06-19 | Rinvoq | $28 |
| Lilly USA | Meals · 2025-06-16 | Omvoh | $35 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-13 | Entyvio | $21 |
| Janssen Biotech | Meals · 2025-06-11 | Tremfya | $27 |
| Celltrion USA | Meals · 2025-06-11 | Vegzelma | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-06 | Entyvio | $23 |
| Pfizer | Meals · 2025-06-06 | Xeljanz | $19 |
| Abbvie | Meals · 2025-06-05 | Skyrizi | $29 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $29 |
| Phathom Pharmaceuticals | Meals · 2025-06-04 | Voquezna | $30 |
| Lilly USA | Meals · 2025-06-03 | Omvoh | $27 |
| Gilead Sciences | Meals · 2025-05-30 | None | $34 |
| Ardelyx | Meals · 2025-05-30 | Ibsrela | $24 |
| Abbvie | Meals · 2025-05-29 | Linzess | $11 |
| Abbvie | Meals · 2025-05-29 | Skyrizi | $27 |
| Madrigal Pharmaceuticals | Meals · 2025-05-28 | Rezdiffra | $28 |
| Abbvie | Meals · 2025-05-27 | Rinvoq | $18 |
| Gilead Sciences | Meals · 2025-05-27 | Livdelzi | $146 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-23 | Entyvio | $13 |
| Janssen Biotech | Meals · 2025-05-22 | Tremfya | $143 |
| Janssen Biotech | Meals · 2025-05-21 | Tremfya | $30 |
| Abbvie | Meals · 2025-05-16 | Viberzi | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-16 | Entyvio | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-16 | Entyvio | $7 |
| Pfizer | Meals · 2025-05-16 | Xeljanz | $24 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $24 |
| Janssen Biotech | Meals · 2025-05-13 | Tremfya | $33 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $32 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-09 | Entyvio | $25 |
| Abbvie | Meals · 2025-05-08 | Creon | $34 |
| Gilead Sciences | Meals · 2025-05-02 | None | $28 |
| Aimmune Therapeutics | Meals · 2025-05-02 | Zenpep | $31 |
| Braintree Laboratories | Meals · 2025-05-01 | Sutab | $27 |
| Abbvie | Meals · 2025-04-30 | Creon | $22 |
| Abbvie | Meals · 2025-04-26 | Skyrizi | $15 |
| Janssen Biotech | Meals · 2025-04-25 | Tremfya | $20 |
| Celltrion USA | Meals · 2025-04-25 | Vegzelma | $28 |
| Braintree Laboratories | Meals · 2025-04-22 | Sutab | $27 |
| Madrigal Pharmaceuticals | Meals · 2025-04-18 | Rezdiffra | $27 |
| Pfizer | Meals · 2025-04-17 | Xeljanz | $19 |
| Pfizer | Meals · 2025-04-16 | Xeljanz | $29 |
| Abbvie | Meals · 2025-04-11 | Skyrizi | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-09 | Entyvio | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-28 | Entyvio | $25 |
| Celltrion USA | Meals · 2025-03-28 | Vegzelma | $26 |
| Abbvie | Meals · 2025-03-27 | Creon | $26 |
| Lilly USA | Meals · 2025-03-24 | Omvoh | $35 |
| Gilead Sciences | Meals · 2025-03-20 | None | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-18 | Eohilia | $24 |
| Lilly USA | Meals · 2025-03-14 | Omvoh | $29 |
| Abbvie | Meals · 2025-03-14 | Rinvoq | $22 |
| Abbvie | Meals · 2025-03-13 | Skyrizi | $116 |
| Janssen Biotech | Meals · 2025-03-12 | Tremfya | $22 |
| Lilly USA | Meals · 2025-03-12 | Omvoh | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-11 | Entyvio | $14 |
| Abbvie | Meals · 2025-03-07 | Rinvoq | $28 |
| Abbvie | Meals · 2025-03-06 | Skyrizi | $26 |
| Janssen Biotech | Meals · 2025-03-04 | Tremfya | $24 |
| Abbvie | Meals · 2025-02-28 | Skyrizi | $25 |
| Celltrion USA | Meals · 2025-02-28 | Vegzelma | $30 |
| Abbvie | Meals · 2025-02-21 | Creon | $20 |
| Abbvie | Meals · 2025-02-21 | Rinvoq | $30 |
| Aimmune Therapeutics | Meals · 2025-02-12 | Zenpep | $27 |
| Janssen Biotech | Meals · 2025-02-07 | Tremfya | $33 |
| Abbvie | Meals · 2025-02-06 | Creon | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-31 | Entyvio | $13 |
| Janssen Biotech | Meals · 2025-01-30 | Tremfya | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-01-30 | Rezdiffra | $25 |
| Abbvie | Meals · 2025-01-24 | Skyrizi | $30 |
| Celltrion USA | Meals · 2025-01-24 | Vegzelma | $19 |
| Janssen Biotech | Meals · 2025-01-22 | Tremfya | $33 |
| Pfizer | Meals · 2025-01-21 | Xeljanz | $14 |
| Abbvie | Meals · 2025-01-17 | Creon | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-01-17 | Dupixent | $28 |
| Abbvie | Meals · 2025-01-16 | Skyrizi | $4 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-15 | Entyvio | $23 |
| Gilead Sciences | Meals · 2025-01-14 | None | $18 |
| Abbvie | Meals · 2025-01-11 | Viberzi | $17 |
| Abbvie | Meals · 2025-01-10 | Rinvoq | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,941
| Abbvie | Creon | $1,040 | 42 payments
|
| Janssen Biotech | Stelara | $547 | 22 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $218 | 10 payments
|
| Lilly USA | Omvoh | $214 | 7 payments
|
| Celltrion USA | Vegzelma | $167 | 8 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $156 | 8 payments
|
| Pfizer | Xeljanz | $133 | 7 payments
|
| Gilead Sciences | None | $76 | 3 payments
|
| Ironwood Pharmaceuticals | Linzess | $61 | 3 payments
|
| Madrigal Pharmaceuticals | Resmetirom | $54 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $53 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $37 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $36 | 2 payments
|
| Fresenius Kabi USA | Idacio | $33 | 1 payment
|
| Aimmune Therapeutics | Zenpep | $29 | 1 payment
|
| Genzyme | Dupixent | $27 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $23 | 1 payment
|
| Braintree Laboratories | Suflave | $23 | 1 payment
|
| Celgene | Zeposia | $14 | 1 payment
|
2023: $2,722
| AbbVie | Rinvoq | $1,052 | 47 payments
|
| Janssen Biotech | Stelara | $517 | 22 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $195 | 10 payments
|
| Celgene | Zeposia | $168 | 12 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $117 | 6 payments
|
| Nestle Healthcare Nutrition | Zenpep | $107 | 4 payments
|
| Pfizer | Xeljanz | $97 | 4 payments
|
| Celltrion USA | Yuflyma | $82 | 3 payments
|
| Genzyme | Dupixent | $81 | 3 payments
|
| Merck Sharp & Dohme | Dificid | $79 | 3 payments
|
| Fresenius Kabi USA | Idacio | $65 | 2 payments
|
| Gilead Sciences | None | $55 | 2 payments
|
| Braintree Laboratories | Sutab | $36 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $30 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $27 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $13 | 1 payment
|
2022: $2,126
| Abbvie | Skyrizi | $698 | 42 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $578 | 33 payments
|
| Janssen Biotech | Stelara | $501 | 24 payments
|
| Braintree Laboratories | Sutab | $160 | 6 payments
|
| Nestle HealthCare Nutrition | Zenpep | $99 | 4 payments
|
| Celgene | Zeposia | $32 | 2 payments
|
| Genzyme | Dupixent | $32 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Gattex | $26 | 1 payment
|
2021: $1,548
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $786 | 49 payments
|
| AbbVie | Humira | $508 | 23 payments
|
| Janssen Biotech | Stelara | $160 | 7 payments
|
| Ferring Pharmaceuticals | Clenpiq | $68 | 4 payments
|
| Celgene | Zeposia | $15 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $11 | 1 payment
|
2020: $933
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $240 | 12 payments
|
| AbbVie | Humira | $235 | 10 payments
|
| Janssen Biotech | Stelara | $210 | 12 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $62 | 2 payments
|
| Gilead Sciences | None | $50 | 2 payments
|
| RedHill Biopharma | Aemcolo | $41 | 3 payments
|
| Pfizer | Xeljanz | $41 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $38 | 2 payments
|
| Ferring Pharmaceuticals | Clenpiq | $16 | 1 payment
|
2019: $1,858
| AbbVie | Mavyret | $285 | 14 payments
|
| Janssen Biotech | Stelara | $250 | 21 payments
|
| Pfizer | Xeljanz | $246 | 7 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $223 | 5 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $205 | 7 payments
|
| Gilead Sciences | None | $187 | 9 payments
|
| Allergan | Zenpep | $170 | 8 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $82 | 5 payments
|
| Intercept Pharmaceuticals | Ocaliva | $57 | 3 payments
|
| Ferring Pharmaceuticals | Clenpiq | $55 | 3 payments
|
| Ucb | Cimzia | $55 | 2 payments
|
| Daiichi Sankyo | Injectafer | $24 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $19 | 1 payment
|
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 78.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Breast cancer screeningEligible women who got a mammogram | 79%That's most of the people this applied to. | 283 |
| Colon cancer screeningEligible adults who got a colon cancer test | 92%That's most of the people this applied to. | 404 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 285 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 55%That's more than half. | 337 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 22%That's few of the people this applied to. | 472 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Implementation of medication management practice improvements
- Lets patients read their visit notes
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports immunizations to the state registry
Professional record
- NPI
- 1649569658
- Licence
- CA A113278California A113278: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-03-30
- NPI last updated
- 2011-03-30
This is when the NPI record was last certified, not a medical board exam.